MedTrace Logo

Efficacy and Safety of CHF 6532 in Patients With Uncontrolled Severe Eosinophilic Asthma

NCT04049175 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 810

Last updated 2022-04-08

No results posted yet for this study

Summary

The purpose of this phase III Study is to demonstrate the efficacy of at least one dose of CHF 6532 on moderate and severe asthma exacerbations rate compared to placebo.

Conditions

  • Asthma; Eosinophilic

Interventions

DRUG

Treatment A

Tablet of CHF 6532

DRUG

Treatment B

Tablet of CHF 6532

DRUG

Treatment C

Tablet of CHF 6532

DRUG

Treatment D

Tablet of CHF 6532 placebo

Sponsors & Collaborators

  • Chiesi Farmaceutici S.p.A.

    lead INDUSTRY

Principal Investigators

  • Pierluigi Paggiaro, MD · Universita di Pisa, Italy

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-28
Primary Completion
2020-10-19
Completion
2021-02-01

Countries

  • Bulgaria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04049175 on ClinicalTrials.gov